These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18855641)

  • 1. Monitoring therapeutic anticoagulation with low molecular weight heparins: is it useful or misleading?
    Hammerstingl C
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):282-6. PubMed ID: 18855641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic indications of low molecular weight heparins].
    Samama MM; Michaut-Paterno F
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of low-molecular-weight heparins in cardiovascular disease.
    Abbate R; Gori AM; Farsi A; Attanasio M; Pepe G
    Am J Cardiol; 1998 Sep; 82(5B):33L-36L. PubMed ID: 9737479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
    Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
    Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
    Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
    J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Heparins].
    Marbet GA
    Ther Umsch; 2003 Jan; 60(1):10-3. PubMed ID: 12638471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
    Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
    Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of heparin therapy beyond the anti-Xa activity assay: Evaluation of a thrombin generation assay.
    Vermeiren P; Vandevelde A; Peperstraete H; Devreese KMJ
    Int J Lab Hematol; 2022 Aug; 44(4):785-795. PubMed ID: 35438827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
    Volovyk Z; Monroe DM; Qi Y; Becker R; Hoffman M
    J Thromb Thrombolysis; 2009 Aug; 28(2):132-9. PubMed ID: 19543696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Old versus new anticoagulants: focus on pharmacology.
    Benmira S; Banda ZK; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):120-37. PubMed ID: 20337579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
    Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
    Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Preliminary results after subcutaneous injection.
    Hemker HC; Béguin S; Bendetowicz AV; Wielders S
    Haemostasis; 1991; 21(4):258-72. PubMed ID: 1665467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: a retrospective study.
    Boban A; Paulus S; Lambert C; Hermans C
    Blood Coagul Fibrinolysis; 2017 Apr; 28(3):199-204. PubMed ID: 27254442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
    Ha NB; Regal RE
    Ann Pharmacother; 2016 May; 50(5):402-9. PubMed ID: 26861989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview of Heparin Monitoring with the Anti-Xa Assay.
    Dean CL
    Methods Mol Biol; 2023; 2663():343-353. PubMed ID: 37204722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels?
    Goland S; Schwartzenberg S; Fan J; Kozak N; Khatri N; Elkayam U
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):451-6. PubMed ID: 24607762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.